Blood Advances · 2022 · 10 citations · 18 references
Life SciencesImmunologyOncologyCancer ImmunologyCellular ImmunologyImmunotherapyAntitumor T Cell ResponsesCancer ImmunotherapyDendritic Cell BiologyNatural Killer Cell BiologyNatural Killer Cell RegulationT Cell Responses To TumorsAdaptive Antitumor ImmunityAntitumor Immune ActivationBcma-directed Bispecific AntibodiesBispecific Antibody ConjugatesCd3-directed Bispecific AntibodiesImmunological MechanismsImmunostimulatory PathwaysInnate Antitumor Immunity
CD3-engaging bispecific antibodies (BsAbs) have emerged as powerful therapeutic approaches by their ability to redirect T cells to eliminate tumor cells in a major histocompatibility complex-independent manner. However, how we can potentiate the efficacy of BsAbs remains largely unknown. To address this question, we investigated immunological mechanisms of action of a BsAb cotargeting CD3 and B-cell maturation antigen (BCMA) in syngeneic preclinical myeloma models. Treatment with the CD3/BCMA BsAb stimulated multiple CD3-expressing T-cell subsets and natural killer (NK) cells in the myeloma bone marrow (BM), highlighting its broad immunostimulatory effect. Notably, the BsAb-mediated immunostimulatory and antitumor effects were abrogated in mice lacking invariant NKT (iNKT) cells. Mechanistically, activation of iNKT cells and interleukin-12 production from dendritic cells (DCs) were crucial upstream events for triggering effective antitumor immunity by the BsAb. Myeloma progression was associated with a reduced number of BM iNKT cells. Importantly, the therapeutic efficacy of a single dose of CD3/BCMA BsAb was remarkably augmented by restoring iNKT cell activity, using adoptive transfer of α-galactosylceramide-loaded DCs. Together, these results reveal iNKT cells as critical players in the antitumor activity of CD3 engaging BsAbs and have important translational implications.
18
Hidemitsu Kitamura, Kenji Iwakabe, Takashi Yahata et al. · The Journal of Experimental Medicine · 1999 · 620 citations · Full text
Saad Z. Usmani, Alfred L. Garfall, Niels W.C.J. van de Donk et al. · The Lancet · 2021 · 312 citations
Medicine, Hematology, Immunology +12
TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma
Camille Guillerey, Heidi Harjunpää, Nadège Carrié et al. · Blood · 2018 · 297 citations · Full text
Life Sciences, Immunology, Oncology +16